We are live on ! Find out more
INO icon

Inovio Pharmaceuticals

125 hedge funds and large institutions have $196M invested in Inovio Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 34 increasing their positions, 38 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more call options, than puts

Call options by funds: $6.66M | Put options by funds: $4.66M

1% more capital invested

Capital invested by funds: $194M → $196M (+$2.21M)

0.05% more ownership

Funds ownership: 2.9%2.95% (+0.05%)

5% less funds holding

Funds holding: 131125 (-6)

11% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 38

31% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 16

Holders
125
Holders Change
-6
Holders Change %
-4.58%
% of All Funds
3.34%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
34
Reduced
38
Closed
16
Calls
$6.66M
Puts
$4.66M
Net Calls
+$2.01M
Net Calls Change
+$573K
Name Holding Trade Value Shares
Change
Change in
Stake
State Street
1
State Street
Massachusetts
$27.8M +$4.37M +39,558 +19%
BFA
2
BlackRock Fund Advisors
California
$26.3M +$1.35M +12,212 +5%
Vanguard Group
3
Vanguard Group
Pennsylvania
$26.2M +$162K +1,462 +0.6%
WA
4
Wasatch Advisors
Utah
$17.4M -$134K -1,217 -0.8%
BIT
5
BlackRock Institutional Trust
California
$17.1M +$165K +1,495 +1%
Northern Trust
6
Northern Trust
Illinois
$7.57M -$28.2K -255 -0.4%
Invesco
7
Invesco
Georgia
$7.43M +$1.17M +10,607 +19%
Morgan Stanley
8
Morgan Stanley
New York
$5.64M +$406K +3,672 +8%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$4.51M +$63.7K +577 +1%
PAM
10
Panagora Asset Management
Massachusetts
$3.72M +$311K +2,815 +9%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$2.98M -$185K -1,677 -6%
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$2.79M -$592K -5,354 -18%
Charles Schwab
13
Charles Schwab
California
$2.55M +$1.42M +12,824 +129%
BIM
14
BlackRock Investment Management
Delaware
$2.42M -$4.75K -43 -0.2%
SIP
15
Stoneridge Investment Partners
Pennsylvania
$2.35M +$715K +6,469 +44%
Arrowstreet Capital
16
Arrowstreet Capital
Massachusetts
$2.24M +$2.21M +20,009 New
New York State Common Retirement Fund
17
New York State Common Retirement Fund
New York
$2.15M +$521K +4,719 +33%
EA
18
Emerald Advisers
Pennsylvania
$1.9M +$449K +4,062 +31%
UBS Group
19
UBS Group
Switzerland
$1.88M -$2.87K -26 -0.2%
PI
20
Putnam Investments
Massachusetts
$1.51M
BG
21
Bellevue Group
Switzerland
$1.45M
Allianz Asset Management
22
Allianz Asset Management
Germany
$1.42M +$145K +1,311 +12%
TA
23
Teachers Advisors
New York
$1.39M
California State Teachers Retirement System (CalSTRS)
24
California State Teachers Retirement System (CalSTRS)
California
$1.31M +$12.9K +117 +1%
Deutsche Bank
25
Deutsche Bank
Germany
$1.22M -$711K -6,438 -37%

INO Hedge Fund Activity: Q3 2016 in Review

125 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q3 2016, worth a combined $196M — up 1.1% from $194M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of INO and 11 opened new positions — a net loss of 5 holders — while 38 trimmed existing stakes and 34 added.

The largest buyer was State Street, adding an estimated $4.37M. The largest seller was Emerald Acquisition, cutting an estimated $1.43M.

  • 125 institutional investors held Inovio Pharmaceuticals (INO) as of Q3 2016, down from 131 in Q2 2016.
  • Funds reported $196M of Inovio Pharmaceuticals stock for Q3 2016, up 1.1% quarter-over-quarter.
  • 11 funds opened new Inovio Pharmaceuticals positions in Q3 2016 and 16 closed out, a net change of -5 holders.
  • The largest Inovio Pharmaceuticals buyer in Q3 2016 was State Street, an estimated $4.37M added.
  • The largest Inovio Pharmaceuticals seller in Q3 2016 was Emerald Acquisition, an estimated $1.43M sold.

Based on aggregated 13F filings for Q3 2016.